Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.

Stryker has been in a holding pattern, posting a small return of 1.1% while floating around $376.76. Is now the time to buy ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other best medical ...

Looking at stock returns, SYK, with 0% returns in the last twelve months, has fared better than ISRG stock, down 20%, and the broader S&P500 index, down 9%.

SYK currently has a PEG ratio of 2.44. Another notable valuation metric for PAHC is its P/B ratio of 3.24. The P/B ratio pits a stock's market value against its book value, which is defined as ...

Investors in Stryker Corp (Symbol: SYK) saw new options begin trading today, for the September 2026 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%. Even if we look at the longer term, SYK stock, with 46% ...

Investors in Stryker Corp (Symbol: SYK) saw new options begin trading today, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK options ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...